Once almost written-off, GSK’s Blenrep now looks like a practice-changing therapy for patients with relapsed/refractory multiple myeloma, after the company unveiled impressive Phase III overall survival data at the American Society of Hematology (ASH) meeting in San Diego, CA.
DREAMM Data Sets GSK’s Blenrep Up For Second Line Myeloma Dominance
Overall survival data presented at ASH and filed with the US FDA puts Blenrep on course for a comeback – something that GSK’s oncology leader said he had never really doubted.
More from ASH
• By
Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.
• By
Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.
• By
With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.
• By
BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.